NCT07570823招募中3 期
A Phase 3 Randomized, Open-label, Multicenter Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin Versus Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
适应症
干预措施
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 101
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age 18-80 years old
- •Histologically confirmed diffuse large B-cell lymphoma according to WHO 2022 criteria
- •Relapsed or refractory (R/R) disease following at least one prior systemic regimen that contained an anti-CD20 monoclonal antibody (mAb) in combination with chemotherapy
- •Participants who have failed after one prior line of therapy are not candidates for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
- •Presence of measurable or evaluable disease at baseline ECOG PS 0-2
- •ECOG PS 0-2
- •Adequate organ function and bone marrow function
- •Expected survival ≥ 3 months
排除标准
- •Prior treatment with antibodies targeting both CD20 and CD3
- •Contraindication to rituximab, gemcitabine or oxaliplatin, or prior treatment with an anti-CD20 antibody in combination with the GemOx regimen
- •Peripheral neuropathy assessed to be Grade >1 according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v6.0 at enrollment
- •Known central nervous system (CNS) involvement by lymphoma
- •Known any major episode of active infection requiring treatment with systemic antibiotics within 2 weeks
- •Treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 100 days prior to first SCTB35 administration
- •Autologous HSCT within 100 days prior to first SCTB35 administration, or any prior allogeneic HSCT or solid organ transplantation
- •Major surgery within 4 weeks prior to first SCTB35 administration
- •Chemotherapy and other non-investigational antineoplastic agents (except CD20 mAbs) within 4 weeks or 5 half-lives (whichever is shorter) prior to first SCTB35 administration
- •Administration of a live, attenuated vaccine within 4 weeks before first study treatment administration or anticipation that such a live, attenuated vaccine will be required during the study
研究组 & 干预措施
R-GemOx
Active Comparator
干预措施: Oxaliplatin (Drug)
SCTB35-GemOx
Experimental
干预措施: SCTB35 injection (Drug)
R-GemOx
Active Comparator
干预措施: Rituxumab (Drug)
SCTB35-GemOx
Experimental
干预措施: Gemcitabine (Drug)
R-GemOx
Active Comparator
干预措施: Gemcitabine (Drug)
SCTB35-GemOx
Experimental
干预措施: Oxaliplatin (Drug)
研究者
研究点 (2)
Loading locations...
相似试验
招募中
3 期
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaFollicular Lymphoma (FL)NCT07562022Sinocelltech Ltd.93
招募中
3 期
A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.NCT07362459Sinocelltech Ltd.246
招募中
3 期
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic DiseaseHR+/HER2- Breast CancerNCT07492641BeOne Medicines1,056
招募中
2 期
TRAP-BTC
Efficacy and safety of GemCis plus Trastuzumab plus Pembrolizumab in previously untreated HER2-positive biliary tract cancer2023-505722-33-00Institut fuer Klinische Krebsforschung IKF GmbH24
招募中
不适用
A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and NeckNCT07546383The Second Affiliated Hospital of Hainan Medical University32